Bayesian secondary reanalysis of published aggregate data on circulating tumor DNA for molecular residual disease detection across cancer types
Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · 23.07.2026
DOI: 10.1177/00045632261475618 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, online erschienen am 23.07.2026. Verfasst von Shugo Yajima und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, National Cancer Center Hospital East, Chiba, Japan. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
Background
Circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) testing may help estimate recurrence risk after treatment. We performed a Bayesian secondary reanalysis of published aggregate data to estimate prognostic and diagnostic performance.
Methods
Data were extracted from Zheng et al. (80 studies, 11 cancer types). Log hazard ratios for recurrence were analyzed using Bayesian normal-normal hierarchical models. Sensitivity and specificity were analyzed using separate logit-scale random-effects models. Posterior probabilities were estimated from posterior samples.
Results
The prognostic analysis included 109 study arms (approximately 9,980 patients). The pooled hazard ratio for recurrence associated with ctDNA positivity was 7.5 (95% credible interval [CrI], 6.4-8.8). Among cancer-type subgroups reported separately, all 95% CrIs excluded 1.0. In 70 diagnostic studies, pooled sensitivity was 57.6% (95% CrI, 53.2-61.9) and specificity was 90.5% (95% CrI, 88.5-92.3). Longitudinal monitoring had higher sensitivity than landmark testing (73.6% vs 50.0%; posterior probability >99.9%), with similar specificity (89.9% vs 90.8%). mPCR-NGS had specificity of 93.2% (95% CrI, 90.2-95.6); in separate exploratory comparisons, P(mPCR-NGS > ddPCR) and P(mPCR-NGS > hybridization capture NGS) were both 96.0%.
Conclusions
This Bayesian secondary reanalysis supports the association between ctDNA-MRD positivity and recurrence risk. Longitudinal monitoring may improve sensitivity, while assay technology comparisons should be interpreted cautiously because they were based on aggregate, non-head-to-head data.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, National Cancer Center Hospital East, Chiba, Japan.
- Department of Urology, Institute of Science Tokyo, Tokyo, Japan.
- Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan.
ORCID-Profile: Shugo Yajima
Zitieren
APA
Yajima, S., Yoshida, S., Chen, W., Fukushima, H., Tanaka, H., Sato, H., Hirakawa, A., Masuda, H., & Fujii, Y. (2026). Bayesian secondary reanalysis of published aggregate data on circulating tumor DNA for molecular residual disease detection across cancer types. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine. https://doi.org/10.1177/00045632261475618
Vancouver
Yajima S, Yoshida S, Chen W, Fukushima H, Tanaka H, Sato H, et al. Bayesian secondary reanalysis of published aggregate data on circulating tumor DNA for molecular residual disease detection across cancer types. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine. 2026. doi:10.1177/00045632261475618
BibTeX
@article{Yajima2026,
author = {Yajima, Shugo and Yoshida, Soichiro and Chen, Wei and Fukushima, Hiroshi and Tanaka, Hajime and Sato, Hiroyuki and Hirakawa, Akihiro and Masuda, Hitoshi and Fujii, Yasuhisa},
title = {Bayesian secondary reanalysis of published aggregate data on circulating tumor DNA for molecular residual disease detection across cancer types},
journal = {Annals of Clinical Biochemistry: International Journal of Laboratory Medicine},
year = {2026},
doi = {10.1177/00045632261475618}
}
EUVIMED